Ascelia Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Ascelia Pharma is Magnus Corfitzen, benoemd in Jan2014, heeft een ambtstermijn van 10.83 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 4.27M, bestaande uit 49% salaris en 51% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.34% van de aandelen van het bedrijf, ter waarde SEK 864.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 7.8 jaar.

Belangrijke informatie

Magnus Corfitzen

Algemeen directeur

SEK 4.3m

Totale compensatie

Percentage CEO-salaris	49.0%
Dienstverband CEO	10.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

Analyse CEO-vergoeding

Hoe is Magnus Corfitzen's beloning veranderd ten opzichte van Ascelia Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 62m
Jun 30 2024	n/a	n/a	-SEK 62m
Mar 31 2024	n/a	n/a	-SEK 89m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 109m
Sep 30 2023	n/a	n/a	-SEK 152m
Jun 30 2023	n/a	n/a	-SEK 157m
Mar 31 2023	n/a	n/a	-SEK 139m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 131m
Sep 30 2022	n/a	n/a	-SEK 113m
Jun 30 2022	n/a	n/a	-SEK 115m
Mar 31 2022	n/a	n/a	-SEK 126m
Dec 31 2021	SEK 15m	SEK 2m	-SEK 126m
Sep 30 2021	n/a	n/a	-SEK 127m
Jun 30 2021	n/a	n/a	-SEK 113m
Mar 31 2021	n/a	n/a	-SEK 111m
Dec 31 2020	SEK 5m	SEK 2m	-SEK 99m
Sep 30 2020	n/a	n/a	-SEK 90m
Jun 30 2020	n/a	n/a	-SEK 88m
Mar 31 2020	n/a	n/a	-SEK 71m
Dec 31 2019	SEK 3m	SEK 992k	-SEK 66m
Sep 30 2019	n/a	n/a	-SEK 46m
Jun 30 2019	n/a	n/a	-SEK 37m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	n/a	n/a	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 22m
Jun 30 2018	SEK 4m	SEK 1m	-SEK 24m

Compensatie versus markt: De totale vergoeding ($USD 385.59K ) Magnus } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.56K ).

Compensatie versus inkomsten: De vergoeding van Magnus is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Magnus Corfitzen (49 yo)

10.8yrs

Tenure

SEK 4,265,000

Compensatie

Mr. Magnus O. Corfitzen serves as the Chief Executive Officer at Ascelia Pharma AB since 2014. He serves as a Director of NsGene A/S. He serves as a Director of DentoFit A/S.Mr. Corfitzen serves on the bo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Magnus Corfitzen	Chief Executive Officer	10.8yrs	SEK 4.27m	0.34% SEK 881.2k
Andreas Norlin	Chief Scientific Officer	2.1yrs	geen gegevens	0.017% SEK 43.4k
Mikael Widell	Head of IR & Communications	6.8yrs	geen gegevens	geen gegevens
Julie Brogren	Deputy CEO & Chief Commercial Officer	4.8yrs	geen gegevens	0.11% SEK 269.2k
Carin Linde	VP of Pharmaceutical Development	no data	geen gegevens	0.43% SEK 1.1m

5.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ACE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Benson	Independent Chairman of the Board of Directors	7.8yrs	SEK 571.00k	0.13% SEK 342.5k
Niels Mengel	Independent Director	24.8yrs	SEK 320.00k	1.3% SEK 3.3m
Hans Maier	Independent Director	7.8yrs	SEK 283.00k	0.021% SEK 53.3k
Lauren Barnes	Independent Director	4.5yrs	SEK 356.00k	geen gegevens
Helena Wennerström	Independent Director	7.8yrs	SEK 363.00k	0.031% SEK 79.9k
Marianne Kock	Director	less than a year	geen gegevens	geen gegevens

7.8yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Ascelia Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Key Executive recently bought kr55k worth of stock

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

VP of Pharmaceutical Development recently bought kr103k worth of stock

Key Executive recently bought kr62k worth of stock

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Recent updates

Key Executive recently bought kr55k worth of stock

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (Publ) Presents Late-Breaking Abstract on Sparkle Data At the American Society of Nephrology Kidney Week Congress 2024

New major risk - Shareholder dilution

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

New major risk - Market cap size

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

VP of Pharmaceutical Development recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Price target decreased to kr59.00

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Ascelia Pharma AB (publ) Announces Change of CFO

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Announces Abstract for Orviglance Comparison Study to Gadolinium Accepted At the Radiology Conference RSNA

Ascelia Pharma AB (publ) Receives Conditional U.S. Food and Drug Administration Acceptance for Orviglance

Chief Executive Officer recently bought kr379k worth of stock

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Chief Executive Officer recently sold kr5.8m worth of stock

Chief Executive Officer exercised options to buy kr11m worth of stock.

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Chief Medical Officer recently bought kr392k worth of stock

Ascelia Pharma AB (publ) Presents Clinical Development Plan for Oncoral as a Novel Chemotherapy

Ascelia Pharma Gets US Patent for Second Generation Mangoral

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Independent Director recently bought kr469k worth of stock

Ascelia Pharma AB (Publ) Announces New Study Shows Mangoral's Lesion Visualization as Effective as Gadolinium Contrast Agent

New 90-day high: kr47.55

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

New 90-day high: kr43.35